Grant: Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
McMaster University
$152,932.00
Revisiting the Pathophysiology of Immune Thrombocytopenic Purpura in the Era of Thrombopoietin Mimetics
FY 2009-10
Summary
Immune thrombocytopenic purpura (ITP) is a common blood disease characterized by low blood platelets (the cells that help prevent bleeding after an injury). ITP affects 1 in 5,000 Canadians with a predilection for women and children, and may cause serious bleeding. A new and effective class of pharmaceuticals for ITP, called TPO-mimetic drugs, works by stimulating the bone marrow to produce more platelets, and their success calls into question common thinking about the cause of ITP. This 3-year research program is designed to answer the question 'Why do TPO-mimetic drugs work in ITP?' and will address fundamental concepts about the cause of this disease.
We will test our hypothesis that the megakaryocyte (the parent cell of platelets in the bone marrow) or key factors regulating megakaryocyte growth are targets of the self-directed antibody ("autoantibody") in ITP. We propose that TPO-mimetic drugs work by overwhelming or bypassing the autoantibody. This research proposal will advance our understanding about ITP in general, may lead to the development of a diagnostic test, and will allow us to predict which patients stand to benefit most from treatment with these expensive medications.
Department
Program
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
188999
Name
Arnold Donald M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Amgen Canada Inc. (Mississauga, ON)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Revisiting the Pathophysiology of Immune Thrombocytopenic Purpura in the Era of Thrombopoietin Mimetics
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$152,932
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Keyworddelim
Anti-Platelet Antibodies; Immune Thrombocytopenia Purpura; Megakaryocytes; Romiplostim; Thrombopoietin
Abstract
Immune thrombocytopenic purpura (ITP) is a common blood disease characterized by low blood platelets (the cells that help prevent bleeding after an injury). ITP affects 1 in 5,000 Canadians with a predilection for women and children, and may cause serious bleeding. A new and effective class of pharmaceuticals for ITP, called TPO-mimetic drugs, works by stimulating the bone marrow to produce more platelets, and their success calls into question common thinking about the cause of ITP. This 3-year research program is designed to answer the question 'Why do TPO-mimetic drugs work in ITP?' and will address fundamental concepts about the cause of this disease.
We will test our hypothesis that the megakaryocyte (the parent cell of platelets in the bone marrow) or key factors regulating megakaryocyte growth are targets of the self-directed antibody ("autoantibody") in ITP. We propose that TPO-mimetic drugs work by overwhelming or bypassing the autoantibody. This research proposal will advance our understanding about ITP in general, may lead to the development of a diagnostic test, and will allow us to predict which patients stand to benefit most from treatment with these expensive medications.
Competitiondate
200909
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Arnold, Donald M
Approvedterm
3 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $152,932~ $0~